Tuberculosis Clinical Trial
Official title:
Real-time Tuberculosis Medication Adherence Intervention in Rural Southwestern Uganda
With an estimated 60,000 people diagnosed with TB (Tuberculosis) annually, Uganda holds the
16th position of the 22 countries with highest cases of TB in the world. The Uganda national
target of utilizing the DOTS (Direct Observed Treatment Short Course) to successfully treat
85% of patients diagnosed with TB has not been met. Currently, the country only detects 49.6%
TB case detection, of which it successfully treats 73%. The DOTS strategy has suffered many
socioeconomic challenges, which have resulted into its abandonment by many of the Ugandan
hospitals. Poor TB medication adherence greatly attribute to the many cases of TB in Uganda.
Causes of non-adherence to TB medication include lack of patient follow-up, patients' lack of
transport to go to the clinics to pick up drugs, patients' forgetfulness. There is evidence
that real time adherence monitoring linked with SMS reminders and social support
notifications can address barriers to sustained ART (antiretroviral therapy) adherence. Such
novel interventions addressing TB medication adherence challenges in low resource settings to
date are limited. The prevailing SMS-based studies for TB medication adherence report mixed
results, do not strategically link interventions with missed doses, and have largely been
implemented in developed countries. To date, little is known about the use of real-time
adherence monitoring technologies for TB medication adherence in resource-limited settings.
The goal of this research is to investigate the use of real time adherence monitoring
technology linked with SMS reminders and notifications for TB medication adherence in rural
southwestern Uganda.
The investigator will develop and quantitatively test a real-time adherence monitoring
intervention with 60 individuals initiating TB treatment, and 40 social supporters. The
investigator will randomize participants (1:1:1) to the following arms: 1) Fixed and linked
SMS reminders, 2) SMS notifications to social supporters, and 3) no SMS (control). All
participants will have adherence monitored in real-time for 6 months.
This study has three major aims (Aims 1, 2 and 3)
Aim 1: Carry out a formative qualitative study to assess barriers and facilitators to TB
medication adherence, and identify optimal SMS reminders, notifications, and initial
feasibility of real time adherence monitoring. 35 TB patients will be recruited from the TB
clinic in Mbarara Regional Referral Hospital (MRRH), and up to 15 social supporters specified
by the TB patients (one per TB patient). Drawing from technology adoption and behavioral
change models, the investigator will use semi-structured interviews to assess the initial
feasibility and acceptability of the intervention, as well the barriers and facilitators to
TB medication adherence, and how they can be addressed using the proposed intervention. The
purpose will be to inform the development the technology necessary to conduct a real-time
intervention involving a wireless monitor and SMS reminders and notifications (Aim 2 and 3).
Aim 2: Develop a TB medication adherence intervention based on SMS reminders (fixed and/or
linked to real-time detection of missed doses) and assess its acceptability, feasibility and
preliminary impact on adherence.
The Investigators will use real-time electronic adherence monitoring (i.e., Wisepill) to
follow 60 TB-infected individuals initiating TB treatment in Mbarara Regional Referral
Hospital (MRRH) for six months. Using a 1:1:1 manner, participants will be randomized to one
of the following three study arms (details of each intervention will be informed by the data
collected in Aim 1):
1. Intervention Arm A: SMS reminders on a fixed schedule
2. Intervention Arm B: SMS reminders linked to missed doses
3. Control: No SMS reminders.
Qualitative interviews to understand the patients experiences with Wisepill adherence
monitoring and the SMS reminders will be carried out, depending on the study arm to which
they are assigned. The first set of interviews for Arms A and B will be conducted at the end
of Month 3 of the study. The second set of interviews is planned to be conducted within two
weeks after the first 24+ hour lapse in Wisepill signal for the participants in the
intervention arms (A and B). If there is no 24+ hour lapse, the interview will take place at
the end of the study. The control participants in Arm C's interview will occur at a
convenient time during Months 3-6. The effect sizes will be estimated by comparing adherence
at the end of six months between each intervention group and the control group. The primary
outcome will be percent adherence.
Treatment outcomes will be defined according to WHO definitions, where cure and completed
treatment are defined as successful treatment outcomes (WHO 2014). Unsuccessful treatment
outcomes for active TB treatment will include death ascertained from hospital death registry,
treatment failure (sputum smear positive at 6 months) and loss to follow-up. Treatment
outcomes will be compared for both intervention and control arms.
Aim 3: Develop a social support intervention linked to real-time adherence monitoring and
assess its acceptability, feasibility and preliminary impact on adherence. Members of
pre-existing social support networks for the same 40 TB-infected individuals in the two
intervention arms described in Aim 2 above will be recruited to receive real-time SMS
notification of sustained non-adherence (i.e., gaps of >24 hours) over the latter four months
of follow-up. The investigators will continue to follow the 20 TB-infected individuals in the
control group (i.e., electronic monitoring alone) to estimate the effect size of the
intervention on adherence at the end of the six-month period. Qualitative interviews to
understand the experiences of participants in each study arm and the social supporters with
special emphasis on understanding mechanisms of effects of the SMS reminders, forms and
dynamics of support, experiences with the SMS reminders/notifications, and technical problems
encountered will be conducted. The results of Aim 3 will be used to determine the types of
SMS (fixed versus linked SMS), and the nature of social support that shows the most promise
for real time intervention on anti-TB medication adherence and cure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |